An Early Phase 1 interventional study of Dobutamine in Burn Surgery and Dobutamine, sponsored by Guangzhou Red Cross Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-16.
Sponsored by Guangzhou Red Cross Hospital · Early Phase 1, Interventional, and Prevention
This is a randomized double-blinded study to investigate in which the groups are designated as the control group and the goal-directed fluid therapy group to further evaluate significant differences in rate of complications during burn surgery.
This is a randomized double-blinded study to investigate the effect of control group and the goal-directed fluid therapy group on complications during surgery of the burn patients. The groups are designated as the control group and the oal-directed fluid therapy group to further evaluate significant differences in complications during the surgery.
719 studies on the registry are indexed under Burns; 145 are open to participants now.
This study's planned enrollment of 100 is above the median of 40 across 524 interventional studies indexed under Burns.
Browse Burns studies →Guangzhou Red Cross Hospital is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
Intervention: administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia. Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution.
Drug: Dobutamine
administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
Complication
perioperative complications
Time frame: One week after operation
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangzhou Red Cross Hospital